Canaccord Genuity Reiterates Buy Rating for Artivion, Inc. (AORT)

Canaccord Genuity has reiterated its buy rating on Artivion, Inc. (NYSE:AORT), setting a price target of $36. This update came from analyst William Plovanic on June 16, 2026. Artivion's shares were trading around $21.09 at the time of the report.

Other Institutional Activity in Artivion

BlackRock, Inc. increased its stake in Artivion by 106,735 shares, ending with a total of 6,474,854 shares valued at approximately $237.1 million. FMR LLC also raised its holdings by 41,560 shares, bringing its total to 2,583,427 shares worth about $94.6 million. On the other hand, Nomura Asset Management International Inc. reduced its position by 157,325 shares, leaving it with 2,456,146 shares valued at $89.9 million. Morgan Stanley added 12,552 shares, holding 2,269,294 shares valued at $83.1 million. State Street Corp increased its holdings by 97,353 shares, totaling 1,682,273 shares worth about $61.6 million.

Artivion Stock Snapshot

Artivion, Inc. (NYSE:AORT) has a market capitalization of approximately $1.02 billion. The company's P/E ratio stands at 84.28, with a forward P/E of 28.47. Artivion's stock has a 52-week low of $19.16 and a high of $48.25. The 50-day moving average is $28.96, while the 200-day moving average is $38.68. The company has a beta of 1.258, indicating moderate volatility compared to the market. Artivion maintains a solid current ratio of 3.857 and a quick ratio of 1.741, with a debt-to-equity ratio of 57.309.

Recent Earnings

In its most recent earnings report, Artivion reported revenue of $458.7 million, reflecting a growth rate of 17.5%. The company achieved a net margin of 2.5% and a return on equity of 3.1%. Earnings per share were reported at $0.25. Artivion is expected to announce its next earnings on August 6, 2026.

Insider Buying and Selling at Artivion, Inc.

On June 11, 2026, Andrew Green, SVP of Regulatory and Quality, executed a planned sale of 44,001 shares at an average price of $20.70. Earlier on the same day, he bought 44,001 shares, although the price was not disclosed. Anthony Semedo engaged in several transactions, including buying 7,576 shares on May 18, 2026, and buying 6,325 shares on June 2, 2026, with the transaction details not fully disclosed.

Analysts Set New Price Targets

On June 16, 2026, Canaccord Genuity maintained its buy rating for Artivion with a $36 price target. Other analysts such as Citizens and Needham have also maintained buy ratings with higher targets of $48 and $44, respectively. The consensus among analysts remains strong buy with a mean target price of $42.0 based on eight opinions.

About Artivion, Inc.

Artivion, Inc. is a healthcare company based in Kennesaw, Georgia, specializing in medical devices and implantable human tissues. The company provides a wide range of products, including prosthetic heart valves, stent graft systems, and surgical sealants. Founded in 1984 and led by CEO James Patrick Mackin, Artivion markets its products primarily to hospitals and healthcare facilities worldwide through a direct sales team. The company employs around 1,800 people.

Bottom Line

Artivion, Inc. continues to attract attention from analysts and institutional investors, with Canaccord Genuity reiterating a buy rating and setting a $36 price target. The company's stock is trading below its 52-week high, offering potential upside as suggested by the analysts' targets. Investors should note that 13F filings and analyst ratings are backward-looking indicators and may not reflect current conditions.